The global market for connected insulin pens could be worth up to $123 million by 2023, according to a report published this year by Research & Markets. Insulin pens, designed for people who control their diabetes with multiple daily injections instead of a pump or wearable patch, are portable devices that were first introduced in 1985 with […]
Eli Lilly (NYSE:LLY) touted data today from a Phase IIIb study of its once-weekly, injectable Type II diabetes medication, Trulicity. The insulin-maker reported that its GLP-1 receptor agonist significantly improved blood sugar control in people with Type II diabetes when added to ongoing treatment with a SGLT-2 inhibitor. Get the full story at our sister site, […]
Setting the stage for a battle with rival Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO) reported data this week from a late-stage trial of its oral formulation of semaglutide, a medication for people with Type II diabetes. The GLP-1 agonist is traditionally administered via injection. Both insulin-makers have approved versions of the injectable semaglutide, but Novo Nordisk is the first […]
Shares in Eli Lilly (NYSE:LLY) fell slightly this morning even though the pharmaceutical company beat analysts’ estimates with its fourth quarter and full-year financial results. The Indianapolis-based company swung to a net loss in the fourth quarter, posting -$1.7 billion, or $1.85 per share, on sales of $6.2 billion for the 3 months ended Dec. 31, for sales […]
The Senate finance committee has approved president Donald Trump’s nominee for chief of the Dept. of Health and Human Services, Alex Azar. The former drug company executive is expected to be confirmed by the full Senate. If confirmed, Azar will succeed Tom Price, who was forced out after reports from Politico revealed he often used pricey charter […]
Medtronic (NYSE:MDT) logged a series of legal wins this week after a federal judge dismissed a whistleblower lawsuit against the medtech titan and the U.S. Supreme Court declined to review a bid over legal fees in a long-running patent spat, upholding Medtronic’s victory from April last year. In a lawsuit brought against Medtronic, Cavallino Consulting alleged […]
Alex Azar, the president’s nominee to head the Dept. of Health & Human Services, has nearly a decade of experience in the pharmaceutical industry – and that experience is either predictive of his inability to act on lowering drug prices or will serve him well as HHS chief, depending on who you ask. At Azar’s […]
Patients who take the most-commonly prescribed diabetes medication, metformin, are the least likely to adhere to a prescribed regimen, according to a study published in the journal Diabetes, Obesity and Metabolism. Researchers from the University of Surrey looked at data from 1.6 million people with Type II diabetes across 48 trials and found that 30% of […]
Companion Medical started selling its smart insulin pen in the U.S. today, according to the San Diego, Calif.-based company. The InPen system, which combines an insulin injector pen and a smartphone app, is compatible with Eli Lilly‘s (NYSE:LLY) Humalog and Novo Nordisk‘s (NYSE:NVO) Novolog fast-acting insulin. Get the full story at our sister site, Drug Delivery Business News.
Novo Nordisk‘s (NYSE:NVO) once-weekly semaglutide injection, Ozempic, has won FDA approval as a therapy for adults with Type II diabetes, the insulin-maker reported today. The injection, given in a pre-filled pen, is a GLP-1 analogue – a drug that trigger the production of insulin, while lessening appetite and food intake. Get the full story at […]
Eli Lilly (NYSE:LLY) yesterday dosed the first patient in a trial of its automated insulin delivery system. The system is a hybrid closed-loop platform that includes a connected insulin pump, a dosing algorithm and a continuous glucose monitor. Get the full story at our sister site, Drug Delivery Business News.